Home LiteratureArticle Details
PMID: 11005561 Published · ppublish English Clinical Trial Controlled Clinical Trial Journal Article Research Support, Non-U.S. Gov't

Preoperative plasma plasminogen activator inhibitor type-1 and serum C-reactive protein levels in patients with colorectal cancer. The RANX05 Colorectal Cancer Study Group.

Annals of surgical oncology ·Vol. 7 ·No. 8 ·2000-09-00 ·Pages 617-23

Nielsen HJ, Christensen IJ, Sørensen S, Moesgaard F, Brünner N

Abstract

Preoperative plasma plasminogen activator inhibitor-1 (PAI-1) is a prognostic variable in patients with colorectal cancer. It has been suggested, however, that plasma PAI-1 is a nonspecific prognostic parameter similar to the acute-phase reactant C-reactive protein (CRP). In the present study we analyzed the association between plasma PAI-1 and serum CRP in patients scheduled for elective resection of colorectal cancer. In addition, the prognostic value of PAI-1 and CRP was studied in this patient cohort. PAI-1 and CRP were analyzed in citrated plasma and serum, respectively, obtained preoperatively from 594 patients. Patients who required preoperative blood transfusion received SAGM blood, in which soluble PAI-1 is not present. None of the patients received pre- or postoperative adjuvant chemotherapy, and all were followed in the outpatient clinic for at least 5 years or until death. The association of PAI-1 and CRP, respectively, with survival was tested using the median value of PAI-1 and the upper normal limit for CRP. Analyses were performed by inclusion of all patients, and in the subgroup of patients, who underwent curative resection. The median follow-up period was 6.8 (5.4-7.9) years. The median value of plasma PAI-1 was 35.8 ng/ml, and values greater than 94 nmol/L identified patients with increased CRP levels. Comparison of the molecules showed that PAI-1 was weakly correlated with CRP (r = .26; P <.0001). Both molecules showed a Dukes independent distribution. In univariate survival analyses high levels of PAI-1 were found associated with poor prognosis and low levels with good prognosis (P = .02, HR: 1.3). Similarly, high levels of CRP were found associated with poor prognosis and low levels with good prognosis (P <.0001, HR: 1.9). In a multivariate statistical analysis including Dukes classification, gender, age, tumor location, perioperative blood transfusion, PAI-1 and CRP, plasma PAI-1 was a dependent prognostic variable, while serum CRP (P <.0001; HR: 1.4; 95% CI: 1.3-1.5) was found to be a Dukes independent prognostic variable. Similar analyses, excluding patients with Dukes' D disease showed serum CRP to be an independent prognostic variable (P <.0001; HR: 1.3: 95% CI: 1.2-1.5). This study did not show a strong correlation between plasma PAI-1 and serum CRP in patients with colorectal cancer. Serum CRP was found to be a Dukes independent prognostic variable in this patient cohort, and was found to identify a subgroup of curatively resected patients at risk for short survival.

MeSH Terms
Adult Aged Aged, 80 and over C-Reactive Protein/metabolism Colorectal Neoplasms/blood,drug therapy,surgery Data Interpretation, Statistical Double-Blind Method Follow-Up Studies Histamine H2 Antagonists/therapeutic use Humans Middle Aged Plasminogen Activator Inhibitor 1/blood Preoperative Care Prognosis Ranitidine/therapeutic use Survival Analysis
Chemicals
Histamine H2 Antagonists Plasminogen Activator Inhibitor 1 Ranitidine C-Reactive Protein
Authors & Affiliations
5 authors, click to expand affiliations / ORCID
Nielsen H J
Department of Surgical Gastroenterology, Hvidovre University Hospital, Denmark. [email protected]
Christensen I J
Sørensen S
Moesgaard F
Brünner N
Article Info
Journal
Annals of surgical oncology
Abbr.
Ann Surg Oncol
ISSN
1068-9265
Published
2000-09-00
Pages
617-23
Language
English
Region
United States
NLM ID
9420840
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]